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Background: Peptide receptor radionuclide therapy (PRRT) is applied in patients with advanced neuroendocrine
tumors. Co-infused amino acids (AA) should prevent nephrotoxicity. The aims of this study were to correlate the
incidence of AA-induced hyperkalemia (HK) (≥5.0 mmol/l) and to identify predictors of AA-induced severe HK (>6.0).
Methods: In 38 patients, standard activity of 177Lu-labelled somatostatin analogs was administered. Pre-therapeutic
kidney function was assessed by renal scintigraphy and laboratory tests. For kidney protection, AA was co-infused.
Biochemical parameters (potassium, glomerular filtration rate, creatinine, blood urea nitrogen (BUN), sodium, phosphate,
chloride, and lactate dehydrogenase (LDH)) were obtained prior to 4 and 24 h after the AA infusion. Incidence of HK
(≥5.0) was correlated with pre-therapeutic kidney function and serum parameters. Formulas for the prediction of severe
HK (>6.0) were computed and prospectively validated.
Results: At 4 h, HK (≥5.0) was present in 94.7% with severe HK (>6.0) in 36.1%. Values normalized after 24 h in 84.2%.
Pre-therapeutic kidney function did not correlate with the incidence of severe HK.
Increases in K+ were significantly correlated with decreases in phosphate (r = −0.444, p < 0.005) and increases in BUN
(r = 0.313, p = 0.056). A baseline BUN of >28 mg/dl had a sensitivity of 84.6% and a specificity of 60.0% (AUC = 0.75) in
predicting severe HK of >6.0 (phosphate, AUC = 0.37).
Computing of five standard serum parameters (potassium, BUN, sodium, phosphate, LDH) resulted in a sensitivity of
88.9% and a specificity of 79.3% for the prediction of severe HK >6.0 (accuracy = 81.6%).
Conclusions: A combination of serum parameters predicted prospectively the occurrence of relevant HK with an
accuracy of 81.6% underlining its potential utility for identifying ‘high-risk’ patients prone to PRRT.
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Peptide receptor radionuclide therapy (PRRT) with
radiolabelled somatostatin agonists such as 90Y- or 177Lu-
labelled-[1,4,7,10-tetraazacyclododecane-NN′,N″,N′″-tetraace-
tic acid]-d-Phe1,Tyr3-octreotoc/-tate) DOTATOC/-TATE
(is routinely used for advanced and/or metastatic neuro-
endocrine tumors (NET) which overexpress somatostatin* Correspondence: lapa_c@ukw.de
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in any medium, provided the original work is preceptor subtype II (SSTR II) [1-3]. Although the treatment
is generally well tolerated, side effects like nausea, myelo-
suppression, and renal failure have been reported [4,5].
Tubular reabsorption and retention of the radiopeptide at
the proximal tubule may lead to an excessive radiation dose
to the kidney. Therefore, pre-therapeutic assessment of
renal function is mandatory and is routinely assessed by
means of laboratory tests (creatinine, glomerular filtration
rate (GFR), and blood urea nitrogen (BUN)) or nuclear
imaging techniques (e.g., renal scintigraphy with 99mTc-
mercapto-acetylglycyl-glycyl-glycine [99mTc-MAG3]).Open Access article distributed under the terms of the Creative Commons
g/licenses/by/4.0), which permits unrestricted use, distribution, and reproduction
roperly credited.
Table 1 Patient characteristics
Retrospective cohort Prospective cohort
Number of subjects 38 38
Mean age (years) 62 ± 14 58 ± 12
Sex 24 males, 14 females 23 males,
15 females
Number of treatment
cycle, mean
3.26 ± 2.00 4.26 ± 2.44
Mean activity (GBq) 23.91 ± 14.67
177Lu-DOTATATE
31.68 ± 19.21
177Lu-DOTATOC
Primary tumor
Pancreatic NET 9 10
Small bowel NET 5 4
Ileum NET 4 6
Cerebral tumor 4 2
NET of unknown origin 4 2
Gastric NET 2 1
MTC 2 2
Caecum NET 2 2
Rectal NET 1 2
Liver NET 1 2
Thymus NET 1 1
Paraganglioma 1 1
Lung NET 1 3
Hemangioendothelioma 1
Main baseline features of the patients enrolled in the study. GBq Gigabecquerels,
177Lu-DOTATATE/-DOTATOC [1,4,7,10-tetraazacyclododecane-NN′, 37 N′′,N′′′-tetraacetic
acid]-d-Phe1,Tyr3-octreotate/-toc, NET neuroendocrine tumor, MTC medullary thyroid
cancer.
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of positively charged amino acids (AA) like L-arginine
and L-lysine have been introduced [6-10]. However, side
effects including nausea, vomiting, and clinically relevant
hyperkalemia have been described [11,12]. In a recent
study including patients with NET undergoing PRRT
with 90Y-DOTATOC, Giovacchini et al. reported the
incidence of hyperkalemia (>5.0 mmol/l) in more than
three-fourths of patients with potassium levels up to
6.7 mmol/l, thereby raising awareness of this poten-
tially life-threatening adverse effect induced by AA-
coinfusion [13].
In clinical routine practice, early or even pre-therapeutic
identification of patients at risk for developing severe
hyperkalemia (>6.0 mmol/l) due to AA-coinfusion would
be of high relevance. Therefore, the aims of this study
were to assess the incidence and severity of hyperkalemia
(≥5.0 mmol/l) and to identify predictors of PRRT-related
severe hyperkalemia (>6.0 mmol/l).
Methods
Study design
The study consists of a retrospective and a prospective
part. In the retrospective analysis, 38 consecutive pa-
tients were included. Incidence and severity of hyper-
kalemia (≥5.0 mmol/l) were correlated with pre-therapeutic
kidney function. Three formulas for the prediction of
severe hyperkalemia (>6.0 mmol/l) were computed retro-
spectively from different combinations of serum parame-
ters. Thereafter, these formulas were prospectively validated
in a cohort including another 38 patients.
This study comprised of only retrospective analysis
of routinely acquired data and therefore the institu-
tional review board (ethics committee of the Medical
Faculty of the University of Würzburg) waived the
requirement for additional approval. All patients gave
written informed consent to receive standard-of-care
PRRT. In October 2013, the routinely administered
amount of AA was reduced from 75 g to 50 g to comply
with the most recent version of the joint International
Atomic Energy Agency (IAEA), European Association of
Nuclear Medicine (EANM), and Society of Nuclear
Medicine and Molecular Imaging (SNMMI) practical
guidance [6].
Patients
From July 2013 to December 2013, 38 consecutive
patients (24 males, 14 females) referred for PRRT
were enrolled. Their mean age was 62 ± 14 years
(range, 24 to 82). The general exclusion criteria, as
defined by the joint IAEA, EANM, and SNMMI practical
guidance, were applied [6]. All patients had progressive
disease. Out of the 38 subjects enrolled, 7 received their
first treatment cycle. The following risk factors for theoccurrence of kidney toxicity were assessed in all patients:
diabetes mellitus (n = 5) and arterial hypertension (n = 12).
Additionally, potassium-sparing anti-hypertensive medica-
tions and long-term use of NSAIDs (n = 17) were recorded.
Pretherapeutic ECG was unremarkable in all patients.
None of the subjects had a history of arrhythmogenic
diseases.
From January 2014 to April 2014, the formulas for
hyperkalemia-risk-assessment derived from the retro-
spective cohort were validated prospectively in 38 add-
itional consecutive subjects (23 males, 15 females; mean
age 58 ± 12 years (range, 24 to 76)). Twenty-two patients
were included and monitored during both treatment
cycles with co-infusion of 75 g and 50 g of AA, as
previously reported [14]. Detailed patient characteristics
are given in Table 1.
Assessment of kidney function
About 2 weeks prior to PRRT, 22 patients underwent renal
scintigraphy with 99mTc-labelled mercaptoacetyltriglycine
(MAG3) on a single head gamma camera (Signature;
Siemens, Erlangen, Germany) equipped with low-energy,
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using a commercially available kit (MAG3, Mallinckrodt
Pharmaceuticals, Neustadt an der Donau, Germany). All
patients were asked to drink at least 250 ml of water
30 min prior to the examination. Imaging started immedi-
ately after injection of 98 ± 6 MBq 99mTc-MAG-3 and was
performed according to national guidelines [15]. Venous
blood samples were drawn from the arm contralateral to
the injection site 20 and 30 min after tracer injection to
allow for calculation of tubular extraction rates
(TER). Sixteen patients underwent renal assessment
by 131I-hippurate on an outpatient basis and were excluded
from this part of the study.
Therapy
Preparation of 177Lu-DOTATATE/-TOC and PRRT
177Lu-DOTATATE/-TOC was prepared with minor
modifications as previously reported [14,16]. All patients
were admitted 1 day prior to therapy to guarantee
adequate hydration (1 l saline) and were hospitalized
for a total of 3 days. In the retrospective group,
37.5 g L-arginine hydrochloride and 37.5 g L-lysine
hydrochloride (75 g total amount of AA, pH 7.0)
were intravenously administered over 4 h beginning
30 min to 1 h prior to PRRT. In the prospective cohort,
amounts of AA infused were changed to 25 g of each
L-arginine and L-lysine (pH 7.0; single-day 50 g
protection-protocol) in order to comply with the joint
IAEA, EANM, and SNMMI practical guidance [6]. No
other fluids were administered. As recently published, the
two different amounts of AA do not result in any differ-
ence in incidence or severity of hyperkalemia [14].
Pre- and post-therapeutic blood samples
One day before, 4 and 24 h after the beginning of
the AA infusion, standard blood values (potassium,
GFR, creatinine, BUN, sodium, phosphate, chloride
[available in all patients] and lactate dehydrogenase
[retrospective cohort: available in n = 36/38, prospect-
ive cohort: all patients]) were assessed. Application
of the tourniquet was used as short as possible to
minimize false-positive potassium values due to
hemolysis. Serum potassium levels were measured
with the indirect ion sensitive electrode (ISE) Cobas
8000 system (Roche Diagnostics, Mannheim, Germany).
All samples were screened for hemolysis. Absorbance
of the diluted serum samples (dilution 1:26) was mea-
sured at 570 (primary wave length) and at 600 nm (sec-
ondary wave length), and hemolysis indices were
calculated according to the manufacturer’s instruction.
Serum samples with hemolysis indices above 90 (equaling
90 mg/dl free hemoglobin) were considered to be
hemolytic and excluded from further evaluation (<3% of
all samples drawn).Analysis and statistics
Student’s t test was used to test for simple differences
between patients with or without hyperkalemia in vari-
ous blood parameters. A p value of 0.05 or less was con-
sidered to be significant. Moreover, we have assumed
that some blood parameters promote and some prevent
hyperkalemia. Therefore, it may be possible that the
human body tries to restore a homeostatic imbalance
by increasing one blood parameter or decreasing another.
Such relationships could not be accounted for by Student’s
t tests. However, linear discriminant analysis makes it
possible to classify patients with different conditions
(e.g., hyperkalemia) on the basis of a set of predictors
(e.g., multiple blood parameters). Hence, we performed
multiple linear discriminant analysis to improve the pre-
diction of severe hyperkalemia (>6.0 mmol/l) by calculat-
ing linear combinations of the relevant blood parameters.
In a backward stepwise analysis, the weakest serum
predictor contributing least to the prediction of severe
hyperkalemia was excluded according to its p value.
Cutoff values for the prediction of severe hyperkalemia
were determined for each formula by receiver operating
characteristic (ROC) analysis [17].
Additionally, in order to test a correlation between
increases of potassium and clinical factors, Pearson’s
correlation was performed. A p value of 0.05 or less
was considered to be significant.Results
AA-induced hyperkalemia (retrospective cohort)
At baseline, mean K+ levels were 4.41 ± 0.37 mmol/l. 4 h
after PRRT, mean serum potassium level increased to
5.90 ± 0.80 mmol/l with values ≥5.0 mmol/l in 36/38
subjects (94.7%; 17/36 subjects with history of potassium-
sparing anti-hypertensive medications and long-term
use of NSAIDs). Thirteen of those 36 patients (36.1%)
experienced severe hyperkalemia >6.0 mmol/l. Only
2/38 subjects did not show elevated K+ levels.
Five of the 13 subjects (38.5%, 2/5 with diabetes)
with severe hyperkalemia became symptomatic with
palpitations and general malaise. In all five patients,
ECG revealed flattened P waves and high peaked T
waves with peak serum potassium levels of 8.5 mmol/
l. These patients required immediate therapy to lower
serum potassium concentrations. We effectively ad-
ministered 10 units of regular insulin in 500 ml of
10% dextrose over 60 min.
At 24 h, K+ levels had almost returned to baseline
levels (mean 4.55 ± 0.42 mmol/l, p > 0.05 compared to
baseline; p < 0.001 compared to 4 h) in 32/38 (84.2%)
subjects. Six of the 38 patients (15.8%) still demonstrated
slightly elevated potassium levels with a maximum of
5.5 mmol/l (Figure 1; Table 2).
Figure 1 Serum potassium concentrations (mmol/l) at baseline, 4 and 24 h after PRRT (retrospective cohort, n = 38).
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clinical factors (retrospective cohort)
All patients presented with normal kidney function
according to 99mTc-MAG3 scintigraphy with a mean TER
of 231 ± 47 ml/min/1.73 m2. The pre-therapeutic TER did
not correlate with the post-therapeutic potassium
level (r = −0.120) and was unable to predict incidence or
severity of hyperkalemia. No cutoff value of minimum
glomerular filtration rate excluding severe hyperkalemia
could be derived from serum blood samples (r = −0.055,
p = 0.74).Table 2 Biochemical parameters of patients at baseline, 4 and
Normal range
Potassium (mmol/l) 3.5 to 5.0
GFR (CKD-EPI) (ml/min/1.73 m2) -
Creatinine (mg/dl) 0 to 0.95
BUN (mg/dl) 10 to 50
Sodium (mmol/l) 135 to 145
Phosphate (mmol/l) 0.87 to 1.45
Chloride (mmol/l) 94 to 110
LDH (U/l) ≤250
Biochemical parameters of patients at baseline, 4 and 24 h after PRRT (retrospective
as mean ± SD. GFR glomerular filtration rate, CKD-EPI Chronic Kidney Disease Epide
mmol/l millimoles per litre, ml/min millilitres per minute, mg/dl milligrams per deciAdditional serum parameters (potassium, BUN, sodium,
phosphate, chloride, LDH) were analyzed (Table 2). Out of
all variables investigated, a pre-therapeutic BUN cut-
off value of >28 mg/dl (defined by ROC analysis) had a
sensitivity of 84.6% and a specificity of 60% in predicting
severe hyperkalemia ≥6.0 mmol/l (area under the curve,
AUC = 0.75). No clinical characteristic including patient
age, cumulative dose, number of treatment cycles,
potentially interfering medications, or clinical risk factors
correlated with the incidence or severity of post-treatment
hyperkalemia (Additional file 1: Table S1).24 h after PRRT
Baseline 4 h 24 h
4.41 ± 0.37 5.9 ± 0.8 4.55 ± 0.42
82.79 ± 25.49 80 ± 23.81 81.22 ± 26.34
0.93 ± 0.28 0.95 ± 0.26 0.97 ± 0.29
33.32 ± 12.89 42.38 ± 12.22 36.95 ± 14.07
138.79 ± 3.03 133.63 ± 3.11 137.42 ± 14.07
1.07 ± 0.19 0.84 ± 0.16 1.21 ± 0.22
99.75 ± 4.3 107.84 ± 3.7 105.32 ± 4.15
218.87 ± 59.98 220.38 ± 55.2 219.36 ± 45.21
cohort; LDH, n = 36/38; all other parameters, n = 38). Values are given
miology Collaboration, BUN blood urea nitrogen, LDH lactate dehydrogenase,
litre, U/l units per litre.
Figure 2 Receiver operating characteristic curves for blood urea nitrogen and phosphate. Receiver operating characteristic (ROC) curves
for (A) serum blood urea nitrogen (BUN) and (B) phosphate for the prediction of severe hyperkalemia (>6.0 mmol/l) after peptide receptor
radionuclide therapy (retrospective cohort, n = 38). BUN demonstrates some value as a single, simply achievable parameter (area under the curve
[AUC] = 0.75) whereas serum phosphate is not a suitable predictor (AUC = 0.37).
Lapa et al. EJNMMI Research  (2014) 4:74 Page 5 of 8We also investigated changes to the baseline to 4-h
post-therapy initiation. Changes in serum BUN tended to
positively correlate with hyperkalemia (r= 0.313; p < 0.056)
(Figure 2A). A significant negative correlation between
increase in serum potassium and phosphate was observed
(r = −0.444; p < 0.005). However, this parameter did not
predict severe hyperkalemia (>6.0 mmol/l) (AUC= 0.37)
(Figure 2B).Calculation of formulas for hyperkalemia-risk-assessment
(retrospective cohort)
In order to improve estimation of the risk of severe
hyperkalemia, several formulas were generated based
on an arbitrarily set cutoff potassium level >6.0 mmol/l
and different serum parameters. Three of these
formulas showed superior results in retrospective
evaluation.
The parameters used in the formulas are the pre-
therapeutic plasma concentrations of potassium (K+,
in mmol/l, available in 38/38 patients), sodium (Na+,
in mmol/l, n = 38/38), phosphate (PO42−, in mmol/l,
n = 38/38), creatinine (Crea, in mg/dl, n = 38/38),
blood urea nitrogen (BUN, in mg/dl, n = 38/38),
lactate dehydrogenase (LDH, in U/l, n = 36/38), as
well as the glomerular filtration rate (GFR, in ml/
min/1.73 m2, n = 38/38).The first formula included all seven parameters:
Formula 1 (n = 36):
X ¼ 1:6⋅Kþ þ 0:055⋅BUN þ 0:004⋅LDH−ð0:243⋅Naþ
þ 3:922⋅PO42− þ 0:009⋅GFRþ 1:358⋅CreaÞ
Defining the cutoff as X ≥ −29.909 resulted in a sensi-
tivity of 84.6% and a specificity of 82.6%, respectively
(AUC = 0.92, accuracy = 83.3%).
GFR and creatinine were omitted in Formula 2:
Formula 2 (n = 36):
X ¼ 1:742⋅Kþ þ 0:045⋅BUN
þ 0:003⋅LDH− 0:252⋅Naþ þ 3:927⋅PO42− 
Based on an AUC of 0.90 for Formula 2, the optimal
cutoff value was defined as X ≥ −29.226 with a sensitivity
of 92.3% and a specificity of 82.6% (accuracy = 86.1%).
Excluding further two parameters (BUN, LDH) while
introducing creatinine led to Formula 3:
Formula 3 (n = 38):
X ¼ 2:046⋅Kþ þ 1:053⋅Crea− 0:305⋅Naþ þ 4:356⋅PO42− 
ROC analysis revealed an AUC of 0.90. A cutoff value
of X ≥ −37.035 resulted in a sensitivity of 92.3% and a
specificity of 72.0% in excluding severe hyperkalemia
Figure 3 Receiver operating characteristic curves for the prediction of severe hyperkalemia (>6.0 mmol/l). Receiver operating characteristic
(ROC) curves for the three formulas computed for the prediction of severe hyperkalemia (>6.0 mmol/l) with (A) seven-, (B) five-, and (C) four-serum
parameters. Pre-therapeutic plasma concentrations of potassium, sodium, phosphate, creatinine, blood urea nitrogen, lactate dehydrogenase, as well
as the glomerular filtration rate were included. All formulas show excellent areas under the curve ranging from 0.90 to 0.92.
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in Figure 3.
Validation of formulas for hyperkalemia-risk-assessment
(prospective cohort)
In a prospective setup, additional 38 patients were
enrolled to validate the formulas: none of the patients
suffered from hyperkalemia prior to PRRT with mean
potassium levels of 4.34 ± 0.39 mmol/l. 4 h after
PRRT, mean K+ level was 5.69 ± 0.61 mmol/l with
values ≥5.0 mmol/l in 28/38 subjects (73.6%; 15/28 sub-
jects with history of potassium-sparing anti-hypertensive
medications and long-term use of NSAIDs). Nine of the
38 patients (23.7%) experienced severe hyperkalemia
>6.0 mmol/l, and three patients became symptomatic with
palpitations and ECG changes. After 24 h, K+ levels
returned to baseline levels (mean 4.53 ± 0.37 mmol/l).
The three formulas were validated using the cutoff
values mentioned above. Formula 1 showed a sensitivity
of 77.8% and a specificity of 79.3% (accuracy = 78.9%) and
Formula 2 had a sensitivity of 88.9% and a specificity of
79.3% (accuracy = 81.6%). Formula 3, including four blood
values, could predict severe hyperkalemia >6.0 mmol/l
with a sensitivity of 66.7% and a specificity of 82.8%
(accuracy = 78.9%).
An overview over the results of the three formulas is
given in Table 3 (retrospective and prospective cohort).Table 3 Overview of results (retrospective and prospective co
Retrospective cohort (75 g AA)
Formula Sensitivity Specificity Accurac
1 84.6 (11/13) 82.6 (19/23) 83.3 (30/
2 92.3 (12/13) 82.6 (19/23) 86.1 (31/
3 92.3 (12/13) 72.0 (18/25) 78.9 (30/
Overview of results (retrospective cohort, Formulas 1 and 2: n = 36; Formula 3: n = 3
accuracy are given in percentage. Numbers in brackets indicate patient numbers. ADiscussion
The high incidence of PRRT-related hyperkalemia in
patients treated for NET has been recently reported [13].
The aim of this study was to identify pre-therapeutic
parameters for prediction of AA-induced hyper-
kalemia in patients undergoing PRRT. Combinations
of serum parameters were retrospectively identified,
and their predictive value was prospectively evaluated.
No single serum parameter could reliably predict the
occurrence of hyperkalemia. In the prospective valid-
ation cohort, a formula including five routine biochemical
serum parameters (potassium, BUN, sodium, phosphate,
LDH; Formula 2) correctly identified 8 of 9 patients
with (sensitivity: 88.9%) and 23 of 29 patients without
hyperkalemia >6.0 mmol/l (specificity: 79.3%); resulting
in an accuracy of 31 of 38 (81.6%).
Showing the highest sensitivity and a false-negative
rate of 11.1%, thus really identifying patients suffering
from clinically relevant hyperkalemia, Formula 2 seems
to be the most promising. Considering a potentially
life-threatening side-effect, this approach might be a
quite valuable tool for the clinical physician planning
PRRT.
Arginine monohydrochloride and lysine monohy-
drochloride, both cationic amino acids, are known to
cause transient hyperkalemia by driving potassium from
the intracellular to the extracellular compartmenthort)
Prospective cohort (50 g AA)
y Sensitivity Specificity Accuracy
36) 77.8 (7/9) 79.3 (23/29) 78.9 (30/38)
36) 88.9 (8/9) 79.3 (23/29) 81.6 (31/38)
38) 66.7 (6/9) 82.8 (24/29) 78.9 (30/38)
8, left; prospective cohort, all formulas: n = 38, right). Sensitivity, specificity, and
A = amino acid solution.
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induced in almost every patient and K+ levels rose by
33.8%. This finding is in line with previous results
[11,13,20]. Thus, close monitoring of patients after
PRRT and evaluation of serum potassium levels should
be mandatory as more than 35% of subjects (13/36)
experienced rises in K+ to > 6.0 mmol/l. Five patients
became symptomatic and required potassium-lowering
interventions (e.g. insulin with glucose). Of note, two
of those patients suffered from diabetes (40% of all
diabetic patients in this cohort), a sub-cohort maybe
especially prone to post-therapeutic hyperkalemia due to
reduced sensitivity to endogenous insulin. An earlier study
has already reported on this pathophysiologic mechanism
[21]. In our study, no significant correlation between
diabetes and incidence or severity of increases in potassium
could be detected; however, this might be related to small
sample sizes.
To prevent potential complications, we aimed to iden-
tify predictors for severe hyperkalemia >6.0 mmol/l to
help the clinician in identifying patients at risk. The only
factor with limited predictive value was an increased
serum BUN. A cutoff value of >28 mg/dl provided a sensi-
tivity of 84.6% but a rather low specificity of 60.0% in
excluding severe hyperkalemia >6.0 mmol/l (AUC= 0.75).
However, since emphasis should be put on high sensitivity,
this marker is suggested as simple first test in evaluating
potentially severe hyperkalemia.
In a more sophisticated approach, a combination of
biochemical markers which are all affected by PRRT was
used to derive three different formulas for predicting the
risk of AA-induced hyperkalemia. The four-to-seven
parameters considered by these formulas can be obtained
from one blood sample. All formulas showed excellent
areas under the curve in retrospective ROC analysis
(range, 0.90 to 0.92).
In order to allow broad applicability, accuracy was
prospectively investigated. In this cohort, the formula
taking into account five serum parameters (potassium,
creatinine, sodium, LDH and phosphate; Formula 2)
demonstrated again both excellent sensitivity (88.9%)
and good specificity (79.3%).
The following limitations have to be considered: in
order to strengthen the statistical power and the prog-
nostic significance of our findings, further studies with
larger patient cohorts need to be performed. Secondly,
almost more than half of the patients were included and
monitored during both retrospective and prospective
treatment cycles with co-infusion of 75 or 50 g of AA.
Moreover, the amount of AA routinely administered was
reduced from 75 to 50 g to comply with the latest joint
IAEA, EANM, and SNMMI practical guidance in October
2013 [6]. Thus, the retrospectively calculated formulas
were derived administering 75 g AA whereas in theprospective part these findings were validated administer-
ing 50 g AA. However, in our intra-individual comparison
of both protocols, incidence and severity of hyperkalemia
do not significantly vary between 75 and 50 g AA, respect-
ively [14]. Due to this finding of our previous study, a
broad applicability in clinical routine is independent from
AA dosing (75 or 50 g, respectively). On a final note, differ-
ent radiolabelled compounds were used. In the prospective
cohort, DOTATATE was replaced by DOTATOC. Esser
and colleagues reported that therapy with 177Lu-octreotate
is preferable due to its higher tumor residence time.
However, this research group did not report on inci-
dence of hyperkalemia after administering both proto-
cols [22].
In conclusion, the high incidence of hyperkalemia in
almost all patients undergoing PRRT requires a high
degree of clinical attention. Serum blood sampling
after treatment is mandatory, given that more than 20% of
patients experience a potentially life-threatening rise in
K+ values to >6.0 mmol/l. Early identification of subjects
at risk who might require immediate therapeutic
intervention would be of great value. To the best of
our knowledge, this is the first attempt to derive a robust
estimate of the risk of AA-induced hyperkalemia in
patients scheduled for PRRT. With an accuracy of
81.6% and a low false-negative rate, we established a
reliable prospectively validated formula assessed by
one simple blood collection selecting ‘high risk’ patients
being vulnerable for severe hyperkalemia. In general, this
formula might be a valuable tool for the clinical physician
planning PRRT and was recently implemented into our
clinical routine.Conclusions
No single serum-based factor can reliably predict post-
therapeutic increases in potassium to values >6.0 mmol/l
after PRRT. Our data suggest that prediction of severe
hyperkalemia using a combination of routine serum
parameters prior to PRRT including potassium, cre-
atinine, sodium, LDH, and phosphate identified ‘high
risk’ patients with an accuracy of 81.6%. We therefore
conclude that this formula is a valuable tool for iden-
tifying patients prone to develop PRRT-associated se-
vere hyperkalemia.Additional file
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